Thomas discusses groundbreaking drugs like movolalapine and obicetrapib that show promise in reducing LP concentration, potentially revolutionizing primary prevention strategies for patients with atherosclerosis. These drugs, targeting apoprotein production, could offer significant reductions in LP levels, paving the way for future outcome studies and FDA approval.
